Macular Edema Incidence/Severity Reduction With Nevanac

PHASE3TerminatedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

August 31, 2011

Conditions
Diabetic Retinopathy
Interventions
DRUG

Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)

One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery

DRUG

Nepafenac ophthalmic suspension vehicle

One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery

Trial Locations (1)

76134

Contact Alcon Call Center For Trial Locations, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00939276 - Macular Edema Incidence/Severity Reduction With Nevanac | Biotech Hunter | Biotech Hunter